Renin-angiotensin system inhibitor and statins combination therapeutics-what have we learnt?

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 7, 2015, Pages 949-953

  Koh, Kwang Kon ^a,b   Sakuma, Ichiro ^c   Hayashi, Toshio ^d   Kim, Sang Hyun ^e   Chung, Wook Jin ^a,b  

^a Gachon University   (South Korea)

^b Gachon Cardiovascular Research Institute   (South Korea)

^c Hokko Memorial Clinic   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Seoul National University College of Medicine   (South Korea)

Author keywords

Cardiovascular disease; Hypercholesterolemia; Hypertension; Renin angiotensin system inhibitors; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; UPREGULATION; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; RENIN-ANGIOTENSIN SYSTEM; RISK;

EID: 84928568761     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1019464     Document Type: Review

References (40)

1. Tarver T. Cancer Facts & Figures 2012. American Cancer Society (ACS). J Consum Health Internet 2012;16(3):366-7
2. Von Hoff D, Ramanathan R, Borad M, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II Trial. J Clin Oncol 2011;29(34):4548-54
3. John P, Butler H, SaifMW. Congestive heart failure secondary to gemcitabine nabpaclitaxel in patients with pancreatic cancer. Anticancer Res 2014;34(12):7267-70
4. Hoy SM. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer. Drugs 2014;74(15):1757-68
5. Authier N, Gillet JP, Fialip J, et al. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001;3(3):301-6
6. Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 2004;6(5):484-94
7. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporine inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 1992;261(2):803-10
8. Vi-udez A, Ramirez N, Hernandez-Garcia I, et al. Nab-paclitaxel: a flattering facelift. Crit Rev Oncol Hematol 2014;92(3):166-80
9. Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nabpaclitaxel in pancreatic cancer. Br J Cancer 2013;109(4):926-33
10. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
11. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37(4):300-11
12. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21(3):418-29
13. Yano S, Zhang Y, Miwa S, et al. Spatial-Temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle 2014;13(13):2110-19
14. Yano S, Zhang Y, Zhao M, et al. Tumor-Targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle 2014;13(24):3683-8
15. Yano S, Tazawa H, Hashimoto Y, et al. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells into S/G2/M phases. Clin Cancer Res 2013;19(23):6495-505
16. Hoffman RM, Jacobsen SJ. Reversible growth arrest in simian virus 40-Transformed human fibroblasts. Proc Natl Acad Sci USA 1980;77(12):7306-10
17. Yano S, Li S, Han Q, et al. Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget 2014;5(18):8729-36
18. Stern PH, Hoffman RM. Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 1986;76(4):629-34
19. Go AS, Bauman M, Coleman King SM, et al. AHA/ACC/CDC Science Advisory: an effective approach to high blood pressure control a science advisory from the american heart association, the american college of cardiology, and the centers for disease control and prevention. J Am Coll Cardiol 2014;63(12):1230-8
20. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
21. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47(4):648-57
22. Sim DS, Jeong MH, Cho KH, et al. Effect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarction. Korean Circ J 2013;43(2):100-9
23. Koh KK, Quon MJ, Han SH, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010;140(1):73-81
24. Lee HY, Sakuma I, Ihm SH, et al. Statins and renin-Angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014;78(2):281-7
25. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42(5):905-10
26. Koh KK, Quon MJ, Han SH, et al. Simvastatin improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008;31(4):776-82
27. Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010;55(12):1209-16
28. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110(24):3687-92
29. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45(6):1088-93
30. Koh KK, Lim S, Choi H, et al. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes 2013;62(10):3547-52
31. Lim S, Sakuma I, Quon MJ, Koh KK. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 2013;167(5):1696-702
32. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18(11):781-8
33. Athyros VG, Katsiki N, Karagiannis A, et al. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharm Des 2014;20(40):6299-305
34. Koh KK, Quon MJ, Sakuma I, et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol 2013;166(2):509-15
35. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380(9841):565-71
36. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a metaanalysis of randomized clinical trials. J Am Coll Cardiol 2005;46(5):821-6
37. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin ii receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95(2):473-8
38. Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated at1 receptor function and density in hypercholesterolemic men. Circulation 1999;100(21):2131-4
39. Oh PC, Choi IS, Ahn T, et al. Predictors of recovery of left ventricular systolic dysfunction after acute myocardial infarction: from the korean acute myocardial infarction registry and korean myocardial infarction registry. Korean Circ J 2013;43(8):527-33
40. Egan BM, Li J, Qanungo S, et al. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation 2013;128(1):29-41